Resonant Capital Advisors’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$416K Buy
1,076
+127
+13% +$47.1K 0.02% 334
2026
Q1
$278K Sell
949
-213
-18% -$70K 0.01% 405
2025
Q4
$407K Buy
1,162
+250
+27% +$84.5K 0.02% 285
2025
Q3
$295K Sell
912
-71
-7% -$22.1K 0.02% 333
2025
Q2
$382K Buy
983
+423
+76% +$170K 0.02% 283
2025
Q1
$244K Sell
560
-36
-6% -$14.5K 0.02% 324
2024
Q4
$220K Sell
596
-125
-17% -$52.3K 0.02% 333
2024
Q3
$375K Buy
721
+220
+44% +$118K 0.03% 242
2024
Q2
$271K Buy
501
+63
+14% +$33.3K 0.02% 286
2024
Q1
$227K Buy
+438
New +$218K 0.02% 312

Other funds holding ELV

Resonant Capital Advisors's ELV Position: Q2 2026 in Review

Resonant Capital Advisors increased its Elevance Health (ELV) stake by 13% in Q2 2026, buying an estimated $47.1K and bringing the position to 1,076 shares worth $416K. The position accounts for 0.02% of the portfolio, ranked #334.

Resonant Capital Advisors first reported a position in ELV in Q1 2024 and has held it in 10 quarters since. 847 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • Resonant Capital Advisors held 1,076 shares of Elevance Health worth $416K as of Q2 2026.
  • Resonant Capital Advisors bought 127 Elevance Health shares in Q2 2026, an estimated $47.1K.
  • Elevance Health made up 0.02% of Resonant Capital Advisors's portfolio in Q2 2026, its #334 holding.
  • Resonant Capital Advisors first reported a position in Elevance Health in Q1 2024 and has held it in 10 quarters since.
  • 847 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on Resonant Capital Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.